Holen Sie sich die Stockscreener-App
1.7467
2.52%
-0.0383
Schlusskurs vom Vortag:
$1.785
Offen:
$1.76
24-Stunden-Volumen:
7,194
Relative Volume:
0.01
Marktkapitalisierung:
$71.77M
Einnahmen:
$90.50M
Nettoeinkommen (Verlust:
$-54.00M
KGV:
-1.3137
EPS:
-1.3296
Netto-Cashflow:
$-32.64M
1W Leistung:
+20.83%
1M Leistung:
+20.00%
6M Leistung:
+2.96%
1J Leistung:
-76.16%
1-Tages-Spanne:
$1.7341
$1.765
1-Wochen-Bereich:
$1.45
$2.16
52-Wochen-Spanne:
$1.31
$8.12
Pulmonx Corp Stock (LUNG) Company Profile
Firmenname
Pulmonx Corp
Sektor
Branche
Telefon
650-364-0400
Adresse
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
1.74 | 75.07M | 90.50M | -54.00M | -32.64M | -1.3296 |
|
ABT
Abbott Laboratories
|
110.14 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
356.22 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.94 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.86 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.38 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | Eingeleitet | D. Boral Capital | Buy |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-04 | Eingeleitet | Lake Street | Buy |
| 2024-02-23 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-25 | Eingeleitet | Piper Sandler | Neutral |
| 2021-03-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-26 | Eingeleitet | BofA Securities | Buy |
| 2020-10-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-10-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Eingeleitet | Stifel | Buy |
| 2020-10-26 | Eingeleitet | Wells Fargo | Equal Weight |
Alle ansehen
Pulmonx Corp Aktie (LUNG) Neueste Nachrichten
Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33) - TradingView
Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens - Quiver Quantitative
Published on: 2026-03-07 07:00:54 - baoquankhu1.vn
Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 Earnings Call Transcript - Insider Monkey
Pulmonx (LUNG): Canaccord Genuity Maintains Buy Rating, Lowers P - GuruFocus
LUNG: Analyst Jason Kolbert Maintains 'Buy' Rating with $14 Targ - GuruFocus
Pulmonx (NASDAQ:LUNG) Given "Buy" Rating at D. Boral Capital - MarketBeat
Pulmonx Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Pulmonx Secures $60 Million Senior Secured Term Loan From Perceptive; $40 Million Drawn - TradingView
Pulmonx Corp (LUNG) Q4 2025 Earnings Call Highlights: Strategic - GuruFocus
Pulmonx (NASDAQ:LUNG) Insider Sells $11,056.76 in Stock - MarketBeat
Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips - Investing.com South Africa
Pulmonx Q4 Earnings Call Highlights - Yahoo Finance
Pulmonx Corporation (LUNG) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Pulmonx closes $60M credit facility with Perceptive Advisors - Investing.com
Pulmonx closes $60 million credit facility with Perceptive - Investing.com
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Pulmonx (LUNG) Exceeds Q4 Revenue Expectations with Strategic Gr - GuruFocus
Pulmonx (LUNG) Projects 2026 Financial Outlook with Revenue and Margin Targets - GuruFocus
Pulmonx earnings beat by $0.14, revenue fell short of estimates - Investing.com
Pulmonx Corporation Reports Fourth Quarter and Full Year 2025 Financial Results, Highlights Transition and Strategic Focus for 2026 - Quiver Quantitative
Earnings Summary: Pulmonx Q4 - Benzinga
Lung device maker Pulmonx trims losses, guides 2026 sales to $90–92M - Stock Titan
Pulmonx Announces Closing of up to $60 Million Credit Facility - Yahoo Finance
Earnings Preview For Pulmonx - Benzinga
LUNG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LUNG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
LUNG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Bitget
Analyst Jason Kolbert Maintains Buy Rating for Pulmonx (LUNG) at $14 Target | LUNG Stock News - GuruFocus
Pulmonx's (LUNG) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Pulmonx Corporation to Announce Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Quiver Quantitative
Pulmonx Stock Pops on Takeover Deal: Cash Exit or Hold Out? - AD HOC NEWS
Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Will Pulmonx Corporation stock outperform Dow Jones index2025 Biggest Moves & Daily Growth Stock Investment Tips - mfd.ru
Pulmonx Stock Under Pressure: Can A Niche Lung-Health Innovator Breathe New Life Into Its Shares? - AD HOC NEWS
Will Pulmonx Corporation stock beat EPS estimatesWeekly Risk Summary & Stock Portfolio Risk Control - mfd.ru
Pulmonx (LUNG) Expected to Announce Earnings on Wednesday - Defense World
Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29% - simplywall.st
Merger Talk: Is Pulmonx Corporation a good ESG investment2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn
Pulmonx Aktie: Zahlen im Fokus - Börse Global
Pulmonx Q4 2025 Results: A Litmus Test for New Leadership - AD HOC NEWS
Sentiment Watch: Is Pulmonx Corporation a turnaround story2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
US Market Wrap: Can Cabaletta Bio Inc disrupt its industryJuly 2025 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Analyzing Pulmonx (NASDAQ:LUNG) and Privia Health Group (NASDAQ:PRVA) - Defense World
Aug Rallies: How Pulmonx Corporation stock compares to growth peersJuly 2025 Gainers & Reliable Volume Spike Alerts - Bộ Nội Vụ
Why The Pulmonx LUNG Narrative Is Shifting After Target Cut And Leadership Return - Yahoo Finance
Is Pulmonx Corporation stock vulnerable to regulatory risks2025 Price Targets & Weekly High Potential Alerts - Улправда
How Pulmonx Corporation stock valuations compare to rivalsTrade Performance Summary & AI Driven Stock Price Forecasts - Улправда
Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of “Hold” by Brokerages - Defense World
Finanzdaten der Pulmonx Corp-Aktie (LUNG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):